Fifty heterosexual male patients with histologically verified genital warts of short duration ( < 3 months) were randomly allocated to treatment with either 0 25% or 05% idoxuridine 
For the purpose of statistical analysis, the treatment result was defined as Cured (all warts had disappeared) or Not Cured (incomplete response or relapse), and Mann-Whitney U-test was used for statistical significance test of the differences between the treatment groups.
Approval for the conduct ofthe study was obtained from the Ethical Committee of the clinic and the Finnish Board of Health prior to study start, and written information regarding the study was given to all patients. An oral informed consent for participation was obtained from all patients before start of treatment.
Results
Clinical and histological features of the warts before Atypical changes 3 4 start of treatment are presented in table 2. The majority of the patients in both groups had warts located only to the mucosa. About one third of the patients in the 025% idoxuridine cream treatment group had warts located only to the skin or to both skin and mucosa, whereas the corresponding proportion of the patients in the 0-500 idoxuridine cream group was one fifth. The number of patients with only exophytic warts was considerably higher in the 0.5% idoxuridine treatment group, but in the comparative group the number of patients with both exophytic and flat warts was higher. In the 0.25% group more patients had flat warts (totally 11, compared with 5 in the 0 5% group). A few patients in both groups were found to have mild atypical changes in the epithelia as shown by histological examination. The follow-up examination results are presented in table 3. After 14 days of treatment approximately one third of the patients treated with 0.25% cream, and about three out of four of the patients treated with 0.5% cream were found to be completely healed. The difference reached a significant level (p < 0.01). At the second follow-up examination two weeks later 13 (52%) of the patients treated with 0.25% idoxuridine cream and 19 (76%) of the No symptoms or signs of local toxic reactions attributable to the treatment were observed by the investigators or reported by the patients.
Discussion
The results of the present study confirm previous reports indicating that topical treatment of genital warts of short duration with idoxuridine is clinically effective.'4 However, only vulvar condylomata have been treated and a 0 25% cream has been used. Our results clearly show that this concentration is less efficient in the treatment of male patients with penile condylomata. We compared 0.5% and 0.25% idoxuridine creams, applied topically twice daily to warts for 14 days, in male patients with either exophytic or flat warts or both types localised on mucosa and/or skin. The higher concentration ofidoxuridine cream, 0.5%, was significantly more effective after 14 days of treatment. As patients showing incomplete or no response to the treatment were retreated for a further period of 14 days, the difference was less pronounced 28 days after the beginning of the study. However, at the last follow-up examination, three months after start oftreatment, the difference in clinical efficacy of the two concentrations used was again significant in favour of the 0 5 O cream.
Since none of the two tested idoxuridine creams caused any toxic reactions, the present results suggest that idoxuridine 0 5% cream may be considered to be a good alternative for local treatment 
